These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.
    Author: Marshall SA, Wilke WW, Chen YS, Pfaller MA, Jones RN.
    Journal: Diagn Microbiol Infect Dis; 1998 Jan; 30(1):65-9. PubMed ID: 9488834.
    Abstract:
    The in vitro activity of cefepime was compared to that of penicillin, piperacillin/tazobactam, ceftazidime, ceftriaxone, imipenem, vancomycin, and teicoplanin by using the broth microdilution method against 129 isolates of Staphylococcus [50 S. aureus and 79 coagulase-negative staphylococci (CoNS], selected for their lack of the mec A gene as determined by the polymerase chain reaction. These isolates were obtained from a recent (1995-1996) surveillance of nearly 5000 nosocomial blood stream isolates from more than 40 geographically diverse U.S. medical centers. These results were compared to CoNS results from the same collection selected for their phenotypic susceptibility to oxacillin (OS; MIC < or = 2 micrograms/ml) regardless of their med A genotype. Cefepime, as well as piperacillin/ tazobactam, ceftriaxone, and imipenem, showed 100% susceptibility against OS and mec A-negative staphylococci. Ceftazidime showed relative resistance (30.2% resistant) against CoNS classified as OS based on phenotypic characteristics (MIC < or = 2 micrograms/mL) as compared to strains of mec A-negative CoNS (5.1% resistant). Accurate phenotypic detection of mec A-positive staphylococci by simple standardized in vitro susceptibility tests becomes very important to guide empirical use of beta-lactams for therapy. Furthermore, previously published MIC90 and range data for broad-spectrum beta-lactams versus OS have been falsely elevated by the presence of mec A-positive strains. The greater use of these potent beta-lactams against true mec A-negative staphylococci should enhance clinical outcomes and reduce the need for vancomycin.
    [Abstract] [Full Text] [Related] [New Search]